PharmaShots Weekly Snapshot (April 15-19, 2019)

1.Almac Diagnostic Collaborates with Queen’s University to Bring Personalized Chemotherapy for Esophageal Cancer

Published: April 18, 2019 | Tags: Almac Diagnostic, Collaborates, Queen’s University, Personalized Chemotherapy, Esophageal Cancer

2. NICE Publishes Final Recommendation for Almirall’s Ilumetri (tildrakizumab) to Treat Moderate-To-Severe Plaque Psoriasis in Adults

Published: April 17, 2019 | Tags: NICE, Publishes, Final Recommendation, Almirall, Ilumetri, tildrakizumab, Treat, Moderate-To-Severe, Plaque Psoriasis, Adults 

3.Mylan and TB Alliance Collaborate to Commercialize Pretomanid in Two Combination Regimens for Tuberculosis

Published: April 18, 2019 | Tags: Mylan, TB Alliance, Collaborates, Commercialize, Pretomanid, Two, Combination Regimens, Tuberculosis

4.AbbVie’s Skyrizi (risankizumab) Receives Health Canada’s Approval for Moderate to Severe Plaque Psoriasis

Published: April 18, 2019 | Tags:  AbbVie, Skyrizi, risankizumab, Receives, Health Canada, Approval, Moderate, Severe, Plaque Psoriasis

5.Pfizer & Eli Lilly Report Results of Tanezumab in Long-Term P-III Study for Osteoarthritis

Published: April 18, 2019 | Tags: Pfizer, Eli Lilly, Report, Results, Tanezumab, Long-Term, P-III, Study, Osteoarthritis, OA

6.World Health Organization (WHO) Reports 10 Guidelines on Digital Health Interventions

Published: April 17, 2019 | Tags: World Health Organization, WHO, Reports, 10, Guidelines, Digital Health Interventions

7.OncoSec Signs Research Agreement with Duke University School of Medicine to Evaluate the Combination of TAVOPLUS with a HER2-Plasmid Vaccine

Published: April 17, 2019 | Tags: OncoSec, Signs, Research Agreement, Duke University School of Medicine, Evaluate, Combination, TAVO, HER2-Plasmid Vaccine

8.Medtronic Reports Results of VenaSeal Closure System in VeClose Extension Study for Chronic Venous Diseases

Published: April 17, 2019 | Tags: Medtronic, Reports, Results, VenaSeal Closure System, VeClose Extension Study, Chronic Venous Diseases

9.CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program

Published: April 17, 2019 | Tags: CASI Pharmaceutical, Signs, Exclusive, Worldwide, License, Agreement, Black Belt, TSK011010, Program

10.Boehringer Ingelheim Collaborates with PureTech to Develop Immuno-Oncology Candidates for Immune Modulation

Published: April 17, 2019 | Tags: Boehringer Ingelheim, Collaborates, PureTech, Develop, Immuno-Oncology, Product, Immune Modulation

11.FDA Orders Immediate Stop on Commercialization of Surgical Mesh for Women with Pelvic Collapse in the US

Published: April 16, 2019 | Tags:   FDA, Orders, Stop, Commercialization, Surgical Mesh, Pelvic Collapse, US

12.Gilead Collaborates with Insitro to Discover and Develop Novel Therapies in Nonalcoholic Steatohepatitis (NASH) for 3yrs.

Published: April 16, 2019 | Tags: Gilead, Collaborates, Insitro, Discover, Develop, Novel Therapies, Nonalcoholic Steatohepatitis, NASH, 3yrs

13.Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays for Adverse Pregnancy Outcomes

Published: April 16, 2019 | Tags: Thermo Fisher, Collaborates, NX Prenatal, Develop, Proteomics Assays, Adverse Pregnancy Outcomes     

14.Novartis Reports Results of Zolgensma (onasemnogene abeparvovec-xioi) in P-III STR1VE Study for Spinal Muscular Atrophy (SMA) Type 1

Published: April 16, 2019 | Tags: Novartis, Reports, Results, P-III, STR1VE Study, Zolgensma, onasemnogene abeparvovec-xioi, Spinal Muscular Atrophy, SMA, Type 1

15.Tessa Collaborates with Merck to Evaluate a Combination Therapy for Metastatic or Recurrent Cervical Cancer

Published: April 16, 2019 | Tags: Tessa, Collaborates, Merck, Evaluate, Combination Therapy, Metastatic, Recurrent, Cervical Cancer

16.Alnylam Initiates P-III ILLUMINATE-B Study of Lumasiran for Primary Hyperoxaluria Type 1 (PH1) in Pediatric Patients

Published: April 15, 2019 | Tags: Alnylam, Initiates, P-III, ILLUMINATE-B, Lumasiran, Primary Hyperoxaluria Type 1, PH1, Pediatric Patients     

17.Janssen Expands Clinical Development for Tremfya(R) (guselkumab) in Familial Adenomatous Polyposis (FAP)

Published: April 15, 2019 | Tags: Janssen, Expands, Clinical Development, Guselkumab, Tremfya(R),  Familial Adenomatous Polyposis, FAP      

18.Eagle Restructured its Licensing Agreement with Teva for Bendeka (bendamustine hydrochloride)

Published: April 15, 2019 | Tags: Eagle, Restructured, Licensing Agreement, Teva, Bendeka, bendamustine hydrochloride    

19.Castle Creek Collaborates with Fibrocell to Develop and Commercialize FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)     

Published: April 15, 2019 | Tags: Castle Creek, Collaborates, Fibrocell, Develop, Commercialize, FCX-007, Gene Therapy, Recessive Dystrophic Epidermolysis Bullosa, RDEB    

20.Novartis Reports FDA’s Acceptance of BLA for Brolucizumab (RTH258) to Treat Wet AMD

Published: April 15, 2019 | Tags: Novartis, Reports, FDA, Acceptance, BLA, Brolucizumab, RTH258, Treat, Wet AMD

21.Santhera to Present Result of DELOS & SYROS Study at the 2019 MDA Clinical and Scientific Conference

Published: April 15, 2019 | Tags:  Santhera; Present; Result; DELOS; SYROS; Study; 2019; Clinical; Scientific; Conference     

22.Dr. Reddy’s to Acquire a Portfolio of 42 Abbreviated New Drug Applications (ANDA) in the US

Published: April 13, 2019 | Tags:  Dr. Reddy’s, Acquire, 42, Abbreviated New Drug Applications, ANDA, US      

23.Tracon Terminates its P-III TAPPAS Trial of TRC105 (carotuximab) + Votrient (pazopanib) for Advanced or Metastatic Angiosarcoma

Published: April 12, 2019 | Tags:  Tracon, Terminate, P-III, TAPPAS Trial, TRC105, carotuximab, Votrient, pazopanib, Advanced, Metastatic Angiosarcoma      

24.Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria

Published: April 12, 2019 | Tags: Alnylam, Reports, Results, Givosiran, P-III, ENVISION, Study, Treat Acute Hepatic Porphyria